Hims & Hers Introduces Access to Generic Semaglutide for Canadian Customers

GLP-1 treatments have transformed obesity and metabolic health, with their significance extending well beyond weight alone. But for many Canadians, the price tag has put them out of reach. That changes today with the introduction of generic semaglutide.

As an obesity medicine specialist practicing in Toronto and Chief Medical Officer of Hims & Hers Canada, what excites me isn't just the medication. It's what this moment represents: more choice, lower costs, and a real shift toward care that's built around the whole patient. Nearly two-thirds of Canadian adults are living with overweight or obesity. The science is there. The treatments are there. Now, so is the access.

Health Canada's authorization of generic semaglutide marks a turning point, not just for Hims & Hers customers, but for the country's broader healthcare landscape. When more affordable options enter the GLP-1 space, it becomes more dynamic, and prices fall across the board. That benefits patients everywhere, regardless of where they seek care. And we believe Canadians deserve the right to choose the path and life that’s right for them, regardless of price. 

But while the power of these treatments has transformed care, I want Canadians to understand that medication alone is not enough to meaningfully combat obesity. It is one tool within a comprehensive care plan. Through Hims & Hers, if prescribed by a licensed healthcare provider, personalized treatment plans start at $149/mo CAD. Our integrated care model also provides customers with access to unlimited and ongoing care team support and evidence-informed resources built around nutrition, movement, and sleep, all designed to support sustainable, lasting health habits.

As with any medication, certain treatments aren’t suitable for all patients — that's why every Hims & Hers customer begins with a personalized clinical assessment by an independent, licensed healthcare provider to ensure treatment is a right fit for them.

I joined Hims & Hers as Chief Medical Officer for Canada to help create a programme built on clinical rigour and a genuine understanding of the Canadian lived experience. Our programme is built on a foundational conviction that obesity is a chronic, complex disease, not a failure of willpower. Every element of how we deliver access to care reflects that. Customers are connected with Canadian providers who understand the healthcare landscape they're navigating, while also bringing the local expertise and clinical rigour this kind of care demands.

Hims & Hers is committed to putting the right tools, the right providers, and the right support into the hands of Canadians who are ready to take control of their health.